OVIDのニュース
Ovid Therapeutics: Q1 Earnings Insights 2023/05/05 13:25:09 Benzinga
Ovid Therapeutics (NASDAQ: OVID ) reported its Q1 earnings results on Friday, May 5, 2023 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Ovid Therapeutics missed estimated earnings by 11.76%, reporting an EPS of $-0.19 … Full story available on Benzinga.com
Ovid Therapeutics GAAP EPS of -$0.19 misses by $0.02, revenue of $0.07M beats by $0.05M 2023/05/05 11:56:36 Seeking Alpha
Ovid Therapeutics press release (NASDAQ:OVID): Q1 GAAP EPS of -$0.19 misses by $0.02.Revenue of $0.07M (-95.2% Y/Y) beats by $0.05M.
Ovid Therapeutics Announces Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda 2023/04/27 18:33:02 Investing.com
https://www.investing.com/news/assorted/ovid-therapeutics-announces-longterm-safety--efficacy-findings-from-soticlestat-open-label-extension-study-presented-by-takeda-432SI-3066691
Ovid Therapeutics Inc PT Raised to $2.50 at Citi 2023/03/15 20:40:05 Investing.com
https://www.investing.com/news/pro/ovid-therapeutics-inc-pt-raised-to-250-at-citi-432SI-3031625
Looking Into Ovid Therapeutics''s Return On Capital Employed 2023/03/15 14:47:48 Benzinga
According to Benzinga Pro data, during Q4, Ovid Therapeutics (NASDAQ: OVID ) posted sales of $46 thousand. Earnings were up 3.87%, but Ovid Therapeutics still reported an overall loss of $11.50 million. In Q3, Ovid Therapeutics brought in $11 thousand in sales but lost $11.97 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Ovid Therapeutics Inc PT Raised to $2.50 at Citi 2023/03/15 20:40:05 Investing.com
https://www.investing.com/news/pro/ovid-therapeutics-inc-pt-raised-to-250-at-citi-432SI-3031625
Looking Into Ovid Therapeutics''s Return On Capital Employed 2023/03/15 14:47:48 Benzinga
According to Benzinga Pro data, during Q4, Ovid Therapeutics (NASDAQ: OVID ) posted sales of $46 thousand. Earnings were up 3.87%, but Ovid Therapeutics still reported an overall loss of $11.50 million. In Q3, Ovid Therapeutics brought in $11 thousand in sales but lost $11.97 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Ovid Therapeutics GAAP EPS of -$0.16 beats by $0.02 2023/03/13 12:20:27 Seeking Alpha
Ovid Therapeutics press release (OVID): Q4 GAAP EPS of -$0.16 beats by $0.02.Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million.
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results 2023/03/13 12:00:00 GlobeNewswire
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.
Ovid Therapeutics Earnings, Revenue Beat in Q3 By Investing.com 2022/11/08 21:11:00 Investing.com
Ovid Therapeutics Earnings, Revenue Beat in Q3
Ovid Therapeutics Earnings, Revenue Beat in Q3 By Investing.com 2022/11/08 21:11:00 Investing.com
Ovid Therapeutics Earnings, Revenue Beat in Q3
Ovid Therapeutics GAAP EPS of -$0.17 beats by $0.04 2022/11/08 13:57:29 Seeking Alpha
Ovid Therapeutics press release (OVID): Q3 GAAP EPS of -$0.17 beats by $0.04.Revenue of $11.1K.The company ended Q3 with cash, cash equivalents and marketable securities of…
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights 2022/11/08 13:00:00 GlobeNewswire
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.
Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/07 12:00:00 GlobeNewswire
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24 th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.